biologic’s first year on the market following the U.S. Food and Drug Administration (FDA) approval in August 2024.

Advancing cutting-edge science and industry-leading medical education

Galderma reinforced its leadership in dermatology through new data presentations and world-class educational programs across global congresses and company-led platforms throughout the third quarter.

At the European Academy of Dermatology and Venereology (EADV) 2025, Galderma presented late-breaking findings on Nemluvio’s mode of action in atopic dermatitis.2Long-term safety and efficacy data of Nemluvio in prurigo nodularis and moderate-to-severe atopic dermatitis up to two years were also shared.3,4In addition, Galderma hosted a symposium on itch, industry hubs on sensitive skin and acne, and multiple “Meet the Expert” sessions. Galderma’s Global Sensitive Skincare Faculty (GSSF) also announced results from a first-of-its-kind real-world clinic
=*=*=*=*=*=
当前为第10/31页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页